BiomX Ltd., a Ness Ziona, Israel-based microbiome company developing customized phage therapies, closed a $32m series B equity financing.
The round was led by existing investors OrbiMed, Johnson & Johnson Innovation – JJDC, Inc., Takeda Ventures, Inc., 8VC, MiraeAsset, Seventure Partners’ Health for Life Capital I, SBI Japan-Israel Innovation Fund and additional European investors and included new investors led by RM Global Partners (RMGP) BioPharma Investment Fund, with participation from Chong Kun Dang Pharmaceutical Corp., Handok, Inc., KB Investment Co., Ltd. and Consensus Business Group.
In conjunction with the investment, Yaron Breski, Managing Director at RM Global Partners, and Eric de la Fortelle, Ph.D., MBA, Venture Partner at Seventure Partners, join BiomX’s Board of Directors.
Proceeds from the financing will be used primarily to advance the company’s leading drug candidates for the treatment of acne and Inflammatory Bowel Disease (IBD) to the clinic.
Led by Jonathan Solomon, CEO, BiomX is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. It discovers and validates proprietary bacterial targets and customizes its natural and engineered phage compositions against these targets.